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ABSTRACT 
The discovery of the breast and ovarian cancer predisposition genes, BRCA1 and BRCA2, has led 
to the development of lifesaving treatments and cancer risk reduction strategies in families who 
carry pathogenic variants.  Genetic testing techniques have improved over the years and 
decreased in cost so that many who meet widely accepted testing guidelines based on family and 
personal histories of cancer are able to afford testing after appropriate counseling.  It has been 
suggested that all women should be offered genetic testing for these genes, regardless of family 
or personal cancer history.  To implement a population-based screening program, primary care 
physicians would need to know about the BRCA genes as well as understand how best to use 
genetic test results based on an individual’s medical history; these providers would also need to 
be willing to incorporate an additional service into their practice.  A questionnaire was developed 
to assess the knowledge and opinions of individuals, within the UPMC network, in the medical 
specialties of obstetrics/gynecology and family medicine with regard to BRCA1/2 and offering 
BRCA1/2 testing to patients.  The average number of knowledge questions that were answered 
correctly, across all 64 participants was 9.5 correct out of 13 questions, for an average score of 
73.4%; only one individual correctly answered all 13 questions.  The question that providers 
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 v 
most often answered incorrectly concerned testing policies for variants of uncertain significance; 
only 29.8% (25/84) correctly answered that they would not test a patient for an unclear genetic 
finding that was found in a relative.  With regard to what would motivate those surveyed to 
incorporate population-based BRCA1/2 testing into their practice, 70.2% (59/84) indicated that 
evidence-based professional society guidelines would be their greatest motivator, while only 
4.8% (4/86) indicated they were not interested or motivated to offer BRCA1/2 testing to their 
patients.  The results of this study will help to guide future educational programs for physicians 
as the BRCA genes are considered for population-based screening.  The public health 
significance of this work is that the public will receive proper counseling and consistent care 
with regard to their BRCA testing, if physicians are trained properly. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
1.1.1 Breast Cancer Genetics 
Hereditary breast and ovarian cancer (HBOC) syndrome is a dominantly inherited cancer 
predisposition syndrome of variable penetrance, which is characterized by multiple family 
members having breast, ovarian, or both cancers, often at an early age <50 years1,2.  A single-
gene predisposition is the suspected cause for an estimated 10% of all breast cancer diagnoses, 
with the predominant pathogenic variants occurring in the BRCA1 and BRCA2 genes, although 
these are not the only breast cancer predisposition genes; thirty to fifty percent of hereditary 
breast cancer cases are due to pathogenic variants in the BRCA genes.  Additionally, pathogenic 
variants in the BRCA genes are responsible for 10% of all ovarian cancers1.   
The BRCA genes are tumor suppressors, meaning their protein products are utilized in the 
DNA repair process1.  BRCA1 was discovered in 1994, is located on chromosome 17, and more 
than 1,200 different variants within it have been reported to cause increased risks of cancer.  
BRCA2 was discovered in 1995, is located on chromosome13, and more than 1,300 variants have 
been found within it.  Inherited BRCA pathogenic variants cause an increased risk of cancer 
when the second copy of the gene gains a pathogenic variant (loss of heterozygosity) allowing a 
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cell to replicate without DNA repair resulting in an accumulation of additional pathogenic 
variants, causing cancer; this is known as the “two-hit hypothesis.1”  
With regard to common pathogenic variants or those known to be associated with certain 
populations, there are three pathogenic variants that are associated with individuals of Ashkenazi 
Jewish descent, in BRCA1 c.68_69delAG and c.5266dupC and in BRCA2 c.5946delT3.  In the 
Ashkenazi Jewish population the incidence of BRCA pathogenic variants is 1 in 40; the general 
population incidence of BRCA pathogenic variants is not exactly known, but is suspected to be 
between 1 in 300 and 1 in 8001.  There are also specific pathogenic variants that are more 
commonly found in the French Canadian population and Icelanders, as well as others; these are 
all called “founder pathogenic variants” as they have been passed down in these populations 
from small ancestral origin groups1,3. 
Women in the general population are at an 8 to 12% lifetime risk of developing breast 
cancer, while pathogenic variants in the BRCA genes contribute a lifetime risk of 60-80% for 
developing breast cancer and a 20-40% lifetime risk of developing ovarian cancer2; BRCA1 has 
traditionally been found to cause a higher risk for ovarian cancer than BRCA24.  These genes also 
carry risks for other cancers: a second or contralateral breast cancer, male breast cancer, 
pancreatic cancer, melanoma (only BRCA2), and prostate cancer.  Other cancer risks have been 
suggested to have an association with the BRCA genes, but these are controversial and not found 
to be increased in all studies4,5. 
Individuals can be assessed for their individual likelihood to carry a BRCA pathogenic 
variant based on their own personal and family histories of cancer.  These factors can then be 
compared to nationally accepted, standard guidelines, and/or used in a risk model. These models 
have been created based on pathogenic variant frequencies and cancer penetrance; these models 
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were developed to help clinicians determine a numerical estimate for the likelihood that an 
individual carries a pathogenic variant in one of their BRCA genes and if that individual is at a 
high risk to develop breast cancer.  If an individual meets set criteria, then she/he is eligible for 
genetic testing and should be counseled appropriately1. 
When an individual is found to carry a pathogenic variant in one of the BRCA genes, 
there are a variety of surveillance, chemoprevention, and risk reducing surgical strategies 
available for consideration1.  Women are recommended to begin breast self-awareness at the age 
of 18, get clinical breast exams every 6 to 12 months starting at age 25, and start annual breast 
MRI’s between the ages of 25 and 29 depending on the breast cancer history within the family.  
After the age of 30 women with BRCA pathogenic variants are recommended to undergo annual 
mammograms and MRIs, preferably one every 6 months; over the age of 75 women should be 
screened based on their provider’s recommendation6.  For comparison, women who are at 
general population risk to develop breast cancer begin mammograms at the age of 40 or ten years 
prior to the earliest diagnosis of breast cancer in their family7; women who carry a variant of 
uncertain significance (VUS) should be managed based on their family history.  Women with 
BRCA pathogenic variants are also given the option of risk reducing prophylactic mastectomies 
which can reduce the risk of developing breast cancer by at least 90%8.  Women with pathogenic 
variants are also given the option of taking Tamoxifen, a chemopreventive agent, which may 
reduce breast cancer risk by 62%1.  To reduce her ovarian cancer risks, a woman who has a 
BRCA pathogenic variant is recommended to have her ovaries and fallopian tubes removed after 
40 years of age or after she has completed her family; another screening possibility, that is not 
the standard of care, is to screen for ovarian cancer through the use of a blood test looking for the 
tumor marker, CA-125, and transvaginal ultrasounds1,6.  Men with BRCA pathogenic variants 
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should begin self-breast exam training and education at age 35, in addition to a clinical breast 
exam annually.  At age 40, men with BRCA2 pathogenic variants are recommended to begin 
annual prostate screening, while those with BRCA1 pathogenic variants should only consider 
prostate screening at that time6.  Anyone who carries a BRCA pathogenic variant should be 
educated on the signs of pancreatic cancer and melanoma; they should also establish care with an 
ophthalmologist and a dermatologist6.  
To provide informed consent, individuals should be educated on the possible risks, 
benefits, implications of, and limitations associated with any genetic testing.  Risks may include: 
psychosocial and emotional impacts, incidental findings such as misattributed paternity, and the 
possibility of being denied life or disability insurance.  Some benefits associated with genetic 
testing include: being better educated about one’s health, having an answer or explanation for a 
family history of a cancer, being able to develop a personalized medical management plan, and 
having peace of mind that increased cancer risks were not passed on to one’s children should a 
person tests negative. Implications associated with genetic testing include: increased cancer 
risks, risk to family members, and having to inform at-risk family members of their chance to 
carry a cancer predisposing pathogenic variant. Some limitations of genetic testing include: 
receiving an ambiguous result known as a variant of uncertain significance or VUS, not finding a 
pathogenic variant to explain a family cancer history, that not all tests are the same or equally 
reliable, and that genes are not the only factors that contribute to cancer9. 
1.1.2 Genetic Testing Guidelines 
Genetic testing for breast cancer predisposition is most often ordered and then subsequently 
covered by insurance if an individual meets a set of criteria.  There are a number of published 
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guidelines that are used to determine eligibility for BRCA1/2 testing.  Including: the National 
Comprehensive Cancer Network (NCCN), the American Cancer Society (ACS), and the United 
States Preventative Services Task Force (USPSTF).  These guidelines rely on personal and 
family cancer histories, of blood relatives only, to determine if an individual is a candidate for 
genetic testing.   
An example of some, but not all, of the BRCA1/2 testing criteria that an individual can 
meet to receive a cancer risk assessment and genetic testing, from the NCCN, are as follows6:  
• A person with a known familial pathogenic variant in BRCA1 or BRCA2 
• A person with a personal history of breast cancer diagnosed at the age of 45 or 
younger 
• A person diagnosed with breast cancer between the ages of 45 and 50 with one of 
the following: 
o An additional primary breast cancer 
o At least one blood relative with a breast cancer at any age 
o At least one relative with pancreatic or prostate cancer 
o An unknown or limited family history 
• A person diagnosed with breast cancer at an age with at least one of the 
following: 
o Of Ashkenazi Jewish ancestry, or any other ethnicity associated with high 
pathogenic variant frequencies 
o Two additional relatives on the same side of the family with breast cancer 
at any age or one relative with breast cancer at or before the age of 50 
o A close relative with ovarian cancer or male breast cancer at any age 
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o Two close relatives with pancreatic and/or prostate cancer at any age 
• Individuals who have had ovarian cancer or male breast cancer 
• For an individual who is unaffected but has a family history of the following: 
o A first or second degree relative who would meet criteria 
o A third degree relative who has had breast cancer and/or ovarian cancer 
who has an additional two relatives with breast cancer, one of which must 
be at the age of 50 or younger, and/or ovarian cancer 
 
1.1.3 Prior Physician Knowledge Studies 
Physician knowledge studies exist within the literature and appear to be conducted with a variety 
of goals in mind.  In preparation for a new wide-spread medical initiative, such as population 
BRCA gene testing, the base-line knowledge of physicians should be assessed.  By determining 
what an average population of physicians knows about a topic, focused education programs and 
support tools can be developed and implemented in preparation for these changes.  A literature 
search of previous studies assessing physician knowledge of breast cancer and breast cancer 
genetics was performed to better understand topics that have been previously assessed in order to 
develop a survey that would include questions that may provide additional information in this 
area.   
Teng, et.al in 2014 assayed 161 physicians including: oncologists, other specialists, and 
general practitioners to examine physicians’ knowledge of cancer genetics, patient family history 
assessment, and attitudes about genetic testing for cancer predisposition using a 
questionnaire10.  Although overall knowledge was found to be “suboptimal,” the study found that 
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breast and ovarian cancer specialists were most proficient in genetic testing knowledge, followed 
by gastrointestinal specialists, “other specialists,” and lastly the general practitioners.  While 
general practitioners had the lowest knowledge scores, they were the most likely to want to 
receive further education on the subject.  Over 90% of the responders thought it was their duty to 
inform a patient about being at high-risk for a hereditary cancer predisposition, prompting them 
to inform those patients that there was testing available and to refer them to a genetic counselor. 
An additional aim of this study was to examine the referrals and referral rates of their study 
population.  Unfortunately, referrals and referral rates could not be measured due to a number of 
factors10. 
An Italian study by Marzuillo and colleagues in 2013 assessed a random sample of 
physicians regarding their knowledge of and attitudes toward predictive testing for the genes 
BRCA1/2 and APC11.  Many of the surveyed physicians thought genetic testing should be 
performed without efficacy or cost-effectiveness data.  A limitation of this study is its lack of 
specialty data on the physician participants.  However, the study found physicians were more 
likely to refer a patient for genetic testing if the patient had asked for the testing.  They also 
found that greater than 90% of the physicians wanted to improve their knowledge of cancer 
genetics and 80% thought they currently had inadequate knowledge.  The study found that 
physicians often over-referred for breast and colorectal cancer because they perceived the 
prevalence of pathogenic variants in predisposing genes to be much higher than in reality.  From 
these data the researchers concluded that physicians are not yet ready to provide cancer genetic 
testing11. 
In a study by Dhar, et.al from 2011, a random sample of physicians which included: 
family medicine specialists, OB/Gyns, general surgeons, internal medicine specialists, and 
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hematology/oncology specialists, all of whom were members of the Texas Medical Association, 
were given hypothetical HBOC patient cases from which they had to identify the correct 
management and recommendations for the patient based on their genetic test results and family 
history.  Results revealed that only 16% of physicians followed NCCN guidelines for 
management of a pathogenic variant positive, unaffected woman.  Family and internal medicine 
practitioners were more likely to recommend too little breast cancer screening; these 
practitioners under-recommended MRIs, prophylactic mastectomies, and bilateral salpingo-
oophorectomies in pathogenic variant-positive women. OB/Gyns and hematology/oncology 
practitioners were more likely to over-recommend surveillance for pathogenic variant-negative 
women; only 43% of these physicians correctly managed a patient in this situation.  This study 
highlighted the need for specialty related education to ensure that both pathogenic variant 
positive and pathogenic variant negative patients receive appropriate cancer screening and 
management. 12. 
In 2005, Wideroff, et.al surveyed 1,251 licensed members of the American Medical 
Association13.  Random physicians of differing specialties were given a questionnaire which 
attempted to assess their knowledge of cancer genetics, predictive genetic testing, and the 
benefits and limitations of genetic testing.  The specialties surveyed were general internal 
medicine, general practice, family practice, obstetrics/gynecology, oncology, general surgery, 
urology, and gastroenterology. The topic of paternal inheritance of the BRCA genes was of 
particular interest to this group who found that overall, only 33% of the surveyed physicians 
agreed with the possibility of paternal inheritance, 50% were unsure and 10% thought it didn’t 
happen; oncologists and OB/Gyns had higher awareness of the possibility of paternal inheritance 
of BRCA genes than family or general practitioners.  Also, only 33% of the surveyed physicians 
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accurately responded that 10% of breast cancers are caused by BRCA pathogenic variants, 25% 
overestimated the number of carriers, and 33% were unsure; again oncologists, general surgeons, 
and OB/Gyns had a higher likelihood of an accurate response than general or family 
practitioners.  This survey also found a trend between decreases in accuracy when answering 
genetic testing questions and the physician’s age but this finding was not statistically significant.  
Generally, this survey showed inconsistent genetics knowledge across specialties, though slight 
correlations were seen between how recent cancer genetics services were provided and accuracy 
of answering.  The strength of this study stems from the fact that it was a national sample of 
physicians and the researchers were able to achieve a response rate of 71%; a limitation is that 
not all of the specialties were equally represented.  Wideroff, et.al concluded with the 
recommendation that provider knowledge of cancer genetics should continue to be improved and 
that motivations of providers to incorporate cancer risk assessment into clinical practice should 
be investigated13. 
A study from Cohn, et.al (2014) assessed the association between prior genetics training 
or knowledge and the rate of patient referral to genetics14.  One-hundred and forty physicians 
from the NYIT College of Osteopathic Medicine database and the American College of 
Osteopathic Family Medicine were recruited to fill out a questionnaire regarding their knowledge 
of HBOC, Lynch syndrome, and familial adenomatous polyposis, this particular paper only 
included analysis of the answers to HBOC questions.  The data from this group indicated a 
correlation between genetics training and increased HBOC knowledge, as well as a correlation 
between increased referrals of high-risk patients and knowledge of HBOC.  Limitations of this 
study include possible reporting biases of the participants on referral frequency, inability to 
compare specific genetics training, and the possibility that the 89% who were invited to, but did 
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not respond to the questionnaire may have been less engaged in genetics.  The authors 
recommended that additional physician knowledge studies be conducted to further define the 
knowledge deficiencies and aid in developing genetics training14. 
A 2013 study from Pal et.al also described physician knowledge and application of BRCA 
genetic testing15.  Their study population encompassed physicians from the state of Florida 
offering BRCA testing who were identified from the Myriad Genetics website.  Of 386 providers 
who were invited to participate, there were 87 respondents.  Providers most often responded 
correctly to questions involving inheritance and pathogenic variant prevalence.  Deficiencies 
were observed in knowledge of management and correct usage of testing; particularly for VUS 
discoveries and when rearrangement testing is warranted.  Based on their findings and due to the 
liabilities associated with inadequate knowledge and training about BRCA, the authors 
recommended an increase in regulations for those ordering cancer genetic testing15. 
In contrast to many of the above studies which indicated a need for more provider 
education, Douma, et.al (2015) found that non-genetics healthcare professionals who are 
currently ordering cancer gene testing are adequately educated and often comfortable with 
obtaining informed consent16.  The clinicians who participated in this study were selected 
because each had self-identified as a provider of cancer genetic services and were members of 
either the Myriad Genetics ‘Find a Healthcare Provider’ database or the National Cancer 
Institute’s Cancer Genetics Services Directory.  Using this method of recruitment, this study had 
a response rate of 11% for a total study population of 44 physicians.  The question that was 
answered incorrectly most often concerned VUS results and the protocol for subsequent testing 
in other family members of a patient.  An additional topic that non-genetics healthcare 
professionals believed to be difficult and that they were uncomfortable addressing were the 
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emotional needs of the patient.  A limitation of this study was the limited response rate, which 
could mean those who did respond were those most interested in and confident with cancer 
genetic testing.  This group thought these physicians had adequate knowledge to provide testing, 
but needed to be better educated on the emotional needs of patients16. 
Review of the literature consistently reveals that practitioners have deficiencies in their 
knowledge of the inheritance of the BRCA1/2 genes, management based on genetic test results 
and the protocols for VUS testing in other family members.  Fortunately, the studies have also 
consistently shown that health care providers are interested in or willing to participate in 
advanced genetics education, which gives hope for future education directives.  However, none 
of the studies aimed to identify the factors that would motivate physicians to incorporate cancer 
genetic testing into their practice. 
1.1.4 Research Supporting Population BRCA1/2 Screening 
In the past several years a number of papers supporting the institution of population-based 
BRCA screening have been published17–20.  These studies have been designed to provide a better 
foundation for implementation of a screening program by trying to answer the points needed for 
fulfillment of criteria for population-based BRCA screening.  One such group designed a study 
designed to answer the question of whether the cancer risks were the same in a random 
population based study as they are in a selected population.    Gabai-Kapara, et.al (2014) 
genotyped more than 8,000 cancer-free Ashkenazi Jewish men, in Israel, for the three BRCA1/2 
founder pathogenic variants in that population17.  After genotyping, those men who had 
pathogenic variants were asked to invite their families to participate and to provide a pedigree.  
The relatives were genotyped and new cumulative incidences of cancer were determined based 
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on these family histories.  This study found the incidence of breast cancer by age 60 was 0.41(± 
0.06) for BRCA1 pathogenic variant carriers and 0.26 (± 0.08) for BRCA2 pathogenic variant 
carriers; the incidences of breast cancer by age 80 were 0.60 (± 0.10) and 0.40 (± 0.11) for 
BRCA1 and BRCA2 respectively.  This study found the cumulative incidences of ovarian cancer 
among pathogenic variant carriers by age 80 to be 0.53 (± 0.11) and 0.62 (± 0.18) for BRCA1 and 
BRCA2 respectively.  This high risk of ovarian cancer in BRCA2 pathogenic variant carriers is 
suspected to be due to the location of the c.5946delT pathogenic variant within the gene which is 
located in an “ovarian cancer cluster region.” Combined cancer incidence values for breast and 
ovarian cancer, by age 80, were also provided and were 0.83 (± 0.07) for BRCA1 pathogenic 
variant carriers and 0.76 (± 0.13) for BRCA2 pathogenic variant carriers.  Interestingly, 51% of 
the families that were identified to carry a pathogenic variant would not have met traditional 
family history criteria for genetic testing.  The authors concluded that though this study was 
performed within an Ashkenazi Jewish cohort, the findings are applicable to the global 
population of BRCA pathogenic variant carriers.  There are a number of reasons that the authors 
formed the conclusion that these results were broadly applicable; first, the finding that 50% of 
the pathogenic variant carriers identified in their cohort would not have been identified if family 
history was assessed, so they would not have been managed for their high risk of developing 
breast and ovarian cancer.  Second, the authors found that the reported frequency of breast 
cancer in their study population matched the rates of breast cancer documented in population 
registries for the birth cohort, so individuals without an apparent family history of breast cancer 
have the same risks as those with family histories.  Third, a population-based program would 
allow a person to receive BRCA1/2 genetic testing regardless of family history or a physician 
referral, when a physician may incorrectly assess a patient’s family history.  These authors 
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believe a BRCA screening program should be developed to reduce the incidences of breast and 
ovarian cancer17. 
Additional population-based BRCA screening trials have compared the quality of life 
outcomes experienced by Ashkenazi Jewish individuals who have been tested for the founder 
pathogenic variants on either a population basis or selected based only on traditional family 
history requirements18.  Manchanda et.al (2014) studied an Ashkenazi Jewish cohort of 1,017 
people in the United Kingdom and using randomization placed them either in a group who would 
be genotyped if they met family history criteria or in a group where all would be genotyped, 
regardless of history.  This research team detailed two main findings; first they found 56% more 
pathogenic variant positive individuals in the population screen group than in the family history-
based group (13:9), the family history based screening missed 5 pathogenic variant positive 
participants.  Second, through post-counseling questionnaires filled out at seven days and three 
months, they found that there was no statistically significant difference between the quality of 
life outcomes between BRCA pathogenic variant carriers and non-carriers and that counseling led 
to a decrease in anxiety and uncertainty18.  Of note, the UK maintains more stringent family 
history testing criteria than the U.S. and this requirement may have affected how many 
noncarriers and family history negative participants were identified. 
Manchanda et.al (2015) also performed a cost-effectiveness analysis of population- 
versus family history-based genetic testing in Ashkenazi Jewish women aged 30 years and 
older19.  This group compared relative health outcomes using quality-adjusted life-years 
(QALYs) and costs of interventions based on known cancer incidences in their population from 
the aforementioned study.  A population-based screening program was calculated to save 0.090 
more life years and 0.101 more QALYs when compared to only utilizing family history-based 
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testing; this is associated with a monetary decrease of £2,079/QALYs, or roughly 
$2,935/QALYs, and a decrease in cancer incidence of 0.34% for ovarian cancer and 0.62% for 
breast cancer.  Costs not included in this analysis comprise the costs of educating the public and 
healthcare professionals, community involvement, and any media campaigns necessary to 
institute a population-based screening program.  This group maintains introducing a population-
based screening program for Ashkenazi Jewish women would save lives and resources; this data 
cannot be extrapolated to a general population due to the high testing costs associated with 
complete gene sequencing and deletion/duplication studies required due to an absence of founder 
pathogenic variants, so further research is necessary19. 
An assessment of clinicians’ views and opinions regarding population screening for 
BRCA pathogenic variants has already been conducted, as clinicians will play a large part in the 
implementation of a new screening program.  A study by Shkedi-Rafir, et.al (2013) surveyed the 
opinions of family practice physicians, geneticists, and genetic counselors in Israel regarding 
population screening within the Ashkenazi-Jewish population20.  Most of their questions focused 
on the amount of agreement or disagreement with statements about benefits and drawbacks as 
well as false reassurance or screening neglect of pathogenic variant negative individuals; 
additional questions sought opinions on optimal age of genetic testing and counseling 
requirements.  Approximately 50% of the surveyed clinicians were in favor of population BRCA 
screening in the Ashkenazi-Jewish population.  An interesting finding was that individuals who 
would wish that they could be tested for a BRCA pathogenic variant, even without family history, 
were more likely to be in favor of population BRCA testing.  Most clinicians surveyed thought 
genetic counseling should occur before genetic testing; but a portion of the family practitioners 
thought genetic counseling should not be compulsory and/or should only be a post-test option for 
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pathogenic variant carriers.  Limitations of this study include its sample size of 204 participants 
due to low response rate, a homogeneous and possibly unrepresentative sample, and no test of 
clinician knowledge of breast cancer genetics.  The lack of heterogeneity stemmed from the fact 
that the majority of their population was young, female responders, which is not representative of 
all of the family practice physicians, geneticists, and genetic counselors in Israel. The authors 
concluded that more evaluation and research is required before a population screening program 
should be implemented20. 
Future studies need to assess genetic counseling strategies for large scale testing and 
outcome testing of population screening initiatives21.  Additional studies to duplicate the findings 
of the studies presented are indicated as well.  Also, these studies were all performed within the 
Ashkenazi Jewish population or with regard to the Ashkenazi Jewish population, since specific 
pathogenic variants could be targeted and costs contained; using similar protocols, these studies 
should be repeated within a broader, general population.  Pilot studies of general population-
based BRCA screening will be critical to investigate the methods of counseling and the 
understanding of patients of their test results22.  These studies are also needed to better 
understand the costs of providing counseling and testing services. 
1.1.5 Opinions on Population BRCA Screening 
Dr. Mary-Claire King, a researcher who played a major role in identifying the BRCA genes,  has 
argued that because a number of studies suggest that cancer risks are similar in women with a 
BRCA pathogenic variant, regardless of family history, and genetic sequencing is readily 
available, a population-based screening effort should be implemented21.  Additionally she 
contends that discovering that a person has a pathogenic variant after they have already been 
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diagnosed with a cancer is a failure of cancer prevention21.  Dr. Mary-Claire King, Dr. Ephrat 
Levy-Lahad, and Dr. Amnon Lahad proposed screening parameters include initiating BRCA 
testing into the standards of care before a woman would need to begin intensive breast 
surveillance and before a risk reducing salpingo-oophorectomy became recommended, 
preferably in her early 30s21,23,24.  Additionally, it is recommended that VUS calls should not be 
reported until they are reclassified; a reference list of known disease-causing pathogenic variants 
should be developed and updated as needed, and only these pathogenic variants should be 
reported in population screening to eliminate the confusion for both providers and the 
patients23,25.  This opinion on VUS reporting is supported by the American College of Medical 
Genetics which recommends only “unambiguous loss-of-function mutations” be reported when 
they are identified as incidental findings on exome sequencing26.  Other plans for population 
cancer genetic screening, include the eventual inclusion of other cancer predisposition genes26. 
There are also arguments against the proposed population BRCA screening.  The primary 
argument involves logistics, ethical, and legal aspects of not reporting VUS calls.  In addition, 
there has not been a study to learn the opinions of the public, physicians, or the laboratories on 
not reporting this data22.  There is also the fact that these unreported variants, which may later be 
reclassified as pathogenic alterations, will then be false-negatives and will be heavily prevalent 
in minority populations.  Another argument against population-based BRCA screening regards 
the availability of BRCA1/2 pathogenic variant testing for all women.  This sentiment is also true 
where follow-up care and surveillance after genetic testing is concerned, preventative measures 
recommended as a result of a finding a BRCA pathogenic variant may not be readily available to 
all women.  Additionally, not all of the recipients of population-based BRCA testing will be able 
to receive genetic counseling services, thus new informed consent and counseling models will 
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need to be developed to accommodate all of the women who will need these services27.  Another 
opinion in favor of waiting to implement population-based screening, expressed by Joy Larsen 
Haidle when she was President-elect of the National Society of Genetic Counselors, indicates the 
need for providers and the general public to be better educated on the risks of hereditary cancer 
so the proper genetics referrals can be made28.  She states: “it is premature to suggest that the 
medical system is prepared to implement general population screening of BRCA1 and BRCA2 
mutations, and more harm than good can happen as a result28.”  In other terms, these nay-sayers 
believe further research and the proper safeguards need to be put in place before population-
based BRCA screening can be implemented.  
1.1.6 Population Screening Guidelines 
There are well established screening guidelines to detect chronic and prevalent diseases early, 
which were created by Wilson and Junger in 196829.  The principles were developed to provide a 
process for deciding which conditions should be screened for due to the complexities involved 
with and maintaining screening practices30.  The ten principles are as follows29: 
“(1) The condition sought should be an important health problem.  
(2) There should be an accepted treatment for patients with recognized disease.  
(3) Facilities for diagnosis and treatment should be available.  
(4) There should be a recognizable latent or early symptomatic stage. 
(5) There should be a suitable test or examination.  
(6) The test should be acceptable to the population.  
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(7) The natural history of the condition, including development from latent to declared 
disease, should be adequately understood.  
(8) There should be an agreed policy on whom to treat as patients.  
(9) The cost of case-finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical care as a 
whole.  
(10) Case-finding should be a continuing process and not a "once and for all" project.” 
These principles were created during a time of significant medical advancement when screening 
was controversial and a process was needed to maintain consistent care for the public30.  
Current genetic population-based screening programs generally focus on autosomal 
recessive conditions and include examples such as  newborn screening programs and pre-
conception cases to identify Tay Sachs carriers in the Jewish population30.  As these principles 
are considered for genetic diseases, some have suggested that Wilson and Junger’s criteria need 
to be reevaluated and updated.  For example, Andermann et.al (2008) developed modifications to 
Wilson and Junger’s criteria which is geared toward genetic screening, based on a review of the 
literature and practitioner consults of what criteria and changes to the criteria had been utilized 
since 1968.  They are as follows30:  
“(1) The screening program should respond to a recognized need.  
(2) The objectives of screening should be defined at the outset.  
(3) There should be a defined target population.  
(4) There should be scientific evidence of screening program effectiveness. 
(5) The program should integrate education, testing, clinical services and program 
management. 
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(6) There should be quality assurance, with mechanisms to minimize potential risks
of screening. 
(7) The program should ensure informed choice, confidentiality and respect for
autonomy. 
(8) The program should promote equity and access to screening for the entire target
population. 
(9) Program evaluation should be planned from the outset.
(10) The overall benefits of screening should outweigh the harm.”
These adapted criteria are intended to be seen as updates and additions to the original criteria, to 
better reflect Westernized medicine and new societal views, as well as to better encompass 
genetic screening concerns.  Andermann, et.al stated, “This approach to screening policy-making 
encourages documentation of evidence, trade-offs, and the reasoning underpinning 
recommendations, thus promoting greater transparency, and allowing decisions to be revisited 
over time30.” 
1.2 SPECIFIC AIMS 
1.2.1 First Aim 
The first aim of this study was to survey the breast cancer genetics knowledge of primary care 
physicians, specifically family practice physicians and OB/Gyns in the UPMC system. 
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1.2.2 Second Aim 
The second aim of this study was to elicit the opinions of primary care physicians on who they 
believe would be the best health care specialist to discuss, order, disclose, and manage patients 
with regard to their BRCA1/2 gene testing.   
1.2.3 Third Aim 
The third aim of this study was to assess what would motivate the study population to 
incorporate new testing or procedures into their practice, in this case, population-based  
BRCA1/2 screening.   
1.3 SIGNIFICANCE 
1.3.1 Significance of the First Specific Aim 
It is assumed that these two groups of providers, obstetrics and gynecology and family practice 
professionals will be the practitioners women will visit most often for their medical care.  Should 
this assumption be correct, then these physicians are the best candidates to implement 
population-based BRCA screening in all women over the age of 30 and will need to have the 
proper knowledge and counseling tools to provide the public with the best care. 
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1.3.2 Significance of the Second Specific Aim 
It is suggested that the providers in question may be the expected ones to implement screening.  
However, their perceptions regarding the best care provider to implement a population-wide 
screening program may be at odds with this expectation.  Knowing who these providers believe 
to be the most qualified to provide population screening may be useful in the implementation of 
a program. 
1.3.3 Significance of the Third Specific Aim 
By illuminating the specific factors that providers consider motivational, these factors can then 
be manipulated and used as focal points to help ensure a more consistent up-take of educational 
materials and an overall smoother transition into population-based screening.    
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2.0  MATERIALS AND METHODS 
This study has been approved as an exempt study by the University of Pittsburgh Institutional 
Review Board, approval number: PRO15030332.  Please see the approval letter in Appendix C. 
2.1 QUESTIONNAIRE DESIGN 
This questionnaire was developed using the surveying tool Qualtrics Survey System (Qualtrics 
LLC), as required by the University of Pittsburgh Institutional Review Board.  A consent form 
educating study participants was developed and was shown before participants initiated the 
questionnaire; the consent form can be found in Appendix A.  The questions used were 
developed, edited, and piloted by individuals in the fields of cancer genetics, public health, 
obstetrics/gynecology, and family medicine.  The process used in the development of some of 
the questions were guided by the physician knowledge surveys previously discussed, as well as 
others10,11, 16,31 ,32.  Additional questions were developed similarly to those on a survey from the 
National Cancer Institute which gave physicians patient scenarios to analyze33.  Furthermore, 
review of research from Boulton, et.al (1996) that assessed providers’ knowledge and thoughts 
with regard to population-based cystic fibrosis screening, gave rise to many of the opinion-based 
questions created for the questionnaire34.  A published literature review by Mikat-Stevens, et.al 
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(2014) based on primary-care provider’s perceived barriers to integrating genetic testing services 
was utilized in the development of some opinion-based questions35. 
Three types of questions were constructed: knowledge, opinion, and demographic.  The 
knowledge-based questions were designed to test the participants basic knowledge of the 
BRCA1/2 genes; topics regarding inheritance, genetic testing, and results interpretation.  Thirteen 
questions were created to assess the participant’s knowledge.  The goals of the opinion questions 
were to gauge participants’ feelings toward population genetic screening and its implementation.  
Finally, the demographic questions were designed to gain a variety of information from the study 
participants in an effort to discover if any defining qualities affect knowledge and opinions of 
breast cancer genetics, genetic testing, and opinions concerning population-based BRCA 
screening. 
This questionnaire was designed specifically for OB/Gyns and family practice or general 
physicians.   Physicians employed at the University of Pittsburgh Medical Center (UPMC) in 
family practice or obstetrics and gynecology were selected as the study population for ease of 
access.  Because healthcare providers are busy, the questionnaire was designed to take no more 
than fifteen minutes of the participant’s time.  No incentive was provided to participants and all 
responses were anonymized.  The questionnaire can be found in Appendix B. 
2.2 QUESTIONNAIRE DISTRIBUTION 
This questionnaire was distributed by Dr. Robert Edwards, Chairman of the Department of 
Obstetrics and Gynecology at Magee-Women’s Hospital of UPMC to the OB/Gyn physicians, 
residents and advanced practice providers of UPMC and by Dr. Mylynda Massart, family 
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practice physician, to the Family Practice physicians, residents, and advanced practice providers 
of UPMC.  Email distribution lists were utilized in the dissemination of the questionnaire.  A 
total of 342 providers were invited to participate; two hundred and forty-five OB/Gyn providers 
and 97 Family Practice providers.  Drs. Edwards and Massart were asked to redistribute the 
questionnaire, using the same mailing lists, a few weeks after the initial distribution in an attempt 
to increase the number of responses. 
2.3 DATA ANALYSIS 
Initial descriptive analyses of the questionnaire data were performed using either Microsoft 
Excel version 14.0.7166.5000 (Microsoft Corporation, Redmond, WA) or the reporting functions 
of Qualtrics.  Participants were only included if they completed the entire questionnaire and 
selected OB/Gyn or Family Medicine as their practice specialty.  Questions which included an 
open response option were reported as is.   
Comparative or analytical statistics were performed using Minitab Express version 1.2.0 
(Minitab Inc., State College, PA).  Comparisons of number of correct responses between the two 
surveyed groups were made utilizing 2-sample t-tests which reported the statistical significance 
of knowledge differences between the OB/Gyn and family medicine groups; comparisons were 
also made between genders and prior experience providing BRCA testing.  Comparisons for 
statistically significant differences between the selected opinions of practice specialties were 
checked by utilizing the Mann-Whitney nonparametric test. 
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3.0  RESULTS 
Three hundred and forty-two healthcare providers received the questionnaire and a total of 104 
individuals began the questionnaire resulting in an initial response rate of 30.4%.  Eighteen 
participants declined to complete the questions resulting in a drop-out rate of 17%.  Thus, the 
data analyzed will encompass the 86 practitioners who elected to complete the questionnaire, 
unless otherwise specified, resulting in a response rate of 25.2%.   
3.1 DEMOGRAPHIC INFORMATION 
The survey was completed by 53 females and 33 males.  The majority of participants, 47%, have 
been in the medical field for more than 15 years.  Those who have been practicing for 10 to 15 
years make up 15% of the surveyed population.  Participants who have been practicing 5 to 10 
years made up 13% of the survey group.  Those who have been in practice for less than 5 years 
made up 16% of those surveyed and there were eight residents who took the questionnaire, 
making up 9% of the sample.  Gender distribution of the participants, broken down by years of 
experience, can be visualized in Figure 1, below.  Unsurprisingly, based on the selected 
population, when asked about practice setting 53% reported that they worked in an academic 
facility.  Additionally, 22% reportedly work in a private practice, 19% work in a hospital-based 
practice, and 6% reported to work in “other” which some reported to mean FQHC (Federally 
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Qualified Health Center) or a community-based facility.  When the participants were asked what 
their practice specialty was 62% reported obstetrics and gynecology, 27% reported family 
practice, one person identified themselves as working in internal medicine, and nine individuals 
responded with “other.” “Other” was then reported to mean advanced practice provider/certified 
nurse midwife (four participants), gynecologic oncologist (two participants), maternal-fetal 
medicine or MFM (two participants), and a single reproductive endocrinologist.  Of, note, for 
ease of further analyses, the two gynecologic oncologists will be excluded from the data as they 
are not directly in the target population.  Additionally, all other participants will be sorted into 
either the OB/Gyn specialty or the family practice specialty for future analyses; the participant 
who selected “internal medicine” will be added to the family practice grouping and those who 
identified as advanced practice providers, MFM, and the reproductive endocrinologist will be 
added to the OB/Gyn group.  For exact numbers of participants in the previously mentioned 
categories, please see Table 1, below.  Two hundred and forty-five individuals were sent 
questionnaires using the OB/Gyn email list and 60 responded.  The response rate for the OB/Gyn 
group is 24.5%.  Ninety-seven questionnaires were sent out using the family medicine emailing 
list and 24 responded for a response rate of 24.7%. 
Participants were also asked some questions regarding their personal experience with 
genetics, BRCA testing specifically, and breast or ovarian cancer.  When asked if the participant 
had received any formal genetics training, outside of their schooling, 87% responded that they 
had not.  Participants were then asked if their current group or practice provides BRCA testing to 
its patients; 20% indicated that they did, 30% responded that they did not, and 50% reported that 
they refer such patients to genetics.  Additionally study participants were asked if they personally 
had ever provided BRCA genetic counseling to a patient and 60% reported that they had not, 
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while 40% indicated that they had provided genetic counseling.  Participants were also asked if 
they had a personal or family history of breast cancer; 77% said no, 2% were unsure, and the 
remaining 21% indicated they did have a personal or family history.  Study participants were 
then asked if they personally have or would wish to receive BRCA gene testing, 84% indicated 
they would not wish to receive BRCA gene testing and an additional 14% indicated they were 
unsure of their interest, leaving only two individuals who have already or would wish to be 
tested for pathogenic variants in the BRCA1/2 genes.  
 
 
 
Figure 1: Participants by Gender and Years of Experience 
  
0 10 20 30 40 50 60
Males
Females
Number of Participants
Study Population by Gender and Experience
In Residency
1-5 yrs
5-10 yrs
10-15 yrs
>15 yrs
 28 
Table 1: Characteristics of the Study Population 
Demographics N (%) 
Gender   
Male 33 (38) 
Female 53 (62) 
Length of time in profession   
Currently a Resident 8 (9) 
<5 years 14 (16) 
5-10 years 11 (13) 
10-15 years 13 (15) 
>15 years 40 (47) 
Type of practice setting   
Private 19 (22) 
Hospital-Based 16 (19) 
Academic 46 (53) 
Other (FQHC, Community) 5 (6) 
Practice Specialty   
OB/Gyn 53 (62) 
Family Practice 23 (27) 
Internal Medicine 1 (1) 
Advanced Practice Provider 4 (4) 
Other (Gyn Onc, Reproductive Endo, MFM) 5 (6) 
Do you/your practice currently provide BRCA testing?   
Yes 17 (20) 
No 26 (30) 
Referred to genetics 43 (50) 
Have you personally provided BRCA1/2 genetic counseling?   
Yes 34 (40) 
No 52 (60) 
Have you received formal genetics education, outside of medical school/training?   
Yes 11 (13) 
No 75 (87) 
Do you have a personal/family history of breast or ovarian cancer?   
Yes 18 (21) 
No 66 (77) 
Unsure 2 (2) 
Have you or would you wish to undergo BRCA1/2 testing?   
Yes 2 (2) 
No 72 (84) 
Unsure 12 (14) 
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3.2 KNOWLEDGE BASE ANALYSIS 
The average score of all participants was 73.4%, or 9.5 questions correct out of 13 total 
knowledge questions.  The average score of the OB/Gyn group was 75.9%, with an average 
number correct of 9.9.  The average score of the family medicine group was 67%, which means 
they, on average got 8.7 questions correct.  A summary of all questions and how the participants 
answered can be found in Table 2, below. 
The first question the participants were asked to answer is how the BRCA1/2 genes are 
inherited, 49 (58.3%) correctly answered autosomal dominant, 14 (16.7%) chose autosomal 
recessive, 2 (2.4%) chose x-linked inheritance, and 19 (22.6%) were unsure how these genes are 
inherited.  All but two of respondents (98.8%) knew that the BRCA genes were not the only 
breast cancer predisposition genes.  Regarding the high BRCA pathogenic variant carrier rate in 
the Ashkenazi Jewish population, 62 (73.8%) respondents knew this population had a higher 
carrier rate than the general population, the remaining respondents either thought this was false 
or were unsure.  Concerning paternal inheritance of the BRCA genes, 81% agreed that a patient 
could inherit a pathogenic variant from their father.  Forty-four participants (52.4%) correctly 
identified that the highest lifetime breast cancer risk associated with the BRCA1 gene is 87%.  
The majority of respondents (97.6%) also correctly agreed that the BRCA genes are also 
associated with increased risks for ovarian cancer; however only 48.8% of participants knew 
which gene carried a higher lifetime risk of developing ovarian cancer.  Furthermore, all but one 
of the respondents (98.8%) also correctly identified the definition of a VUS. 
Regarding testing pathways, the majority of participants (76.2%) knew that an unaffected 
individual is not the best person to initiate testing in a family, unless the other family members 
who have had cancer are no longer living or if they are unwilling to be tested.  Additionally, 
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when a patient has a family member who is identified to carry a VUS, only 25 (29.8%) 
participants correctly indicated a healthy patient does not need to be tested for that variant; 30 
(35.7%) respondents were unsure if that patient should receive genetic testing and 29 (34.5%) 
respondents thought that patient should receive testing for the variant.  When asked about the 
mode of testing for a patient whose family has been found to carry a known pathogenic BRCA 
pathogenic variant, 55 (65.5%) participants correctly identified that site-specific or single-site 
analysis for the familial pathogenic variant would be warranted; 23.8% thought the patient 
should receive complete BRCA1/2 sequencing, 9.5% thought the patient should receive BRCA1/2 
sequencing and deletion/duplication studies, and one participant selected whole exome 
sequencing as the best genetic testing option for the patient. 
Regarding management based on test results, the majority of participants (86.9%) agreed 
that a patient with a VUS should receive treatment based on her family history.  Similarly, 88.1% 
correctly identified that a patient who is found to not carry a familial pathogenic variant would 
have the risk to develop breast cancer similar to that of the general population. 
To best analyze the knowledge of the participants, a t-test was performed to show the 
differences between the numbers of correctly answered questions of participants in the OB/Gyn 
specialty versus those in the Family Practice specialty.  The OB/Gyn group received significantly 
overall higher knowledge scores than the family practice group (p=0.016).  A box-plot of the 
distribution of scores in each of the two groups is shown in Figure 2; group 1 represents the 
OB/Gyn participants and group 2 represents the family practice physicians.  The maximum score 
from the OB/Gyn group was 12/13 and the lowest score was 6/13.  The maximum score from the 
family practice group was 13/13, only one individual answered all 13 questions correctly, and the 
minimum score was also 6/13.  Additional findings of interest, there was no significant 
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difference in knowledge between genders (average scores equaled 9.5 and 9.6 in women and 
men respectively), but unsurprisingly, individuals who had previously provided BRCA testing 
and counseling were found to have increased knowledge of BRCA testing (average scores 
equaled 10 and 9.2, respectively; p= 0.042). 
 
 
 
Figure 2: Boxplot of Correctly Answered Questions by Specialty 
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Table 2: Frequency of Correct Responses to each Knowledge Question 
Question Correct   n (%)  
What is the mode of inheritance for pathogenic variants in the BRCA 
genes? 
49 (58)  
True or false, BRCA1/2 pathogenic variants account for all 
hereditary breast cancers. 
83 (99)  
The BRCA pathogenic variant carrier rate in individuals of 
Ashkenazi Jewish (Eastern European Jewish) ancestry is higher than 
the carrier rate of the general population. 
62 (74)  
Your patient has an aunt on her father’s side who is a carrier of a 
BRCA1 pathogenic variant.  Is it possible that your patient could also 
carry this pathogenic variant? 
68 (81)  
Your 35 year old female patient tests positive for a BRCA1 gene 
pathogenic variant.  What is her highest lifetime risk of developing 
breast cancer? 
44 (52)  
Your healthy patient tests positive for a BRCA pathogenic 
variant.  She has an increased risk for breast and ovarian cancer. True 
or false? 
82 (98)  
Your patient’s maternal family history is significant for breast cancer 
diagnosed prior to age 50 in several women.  Several of the affected 
women are still living but have not been tested for pathogenic 
variants in BRCA1/2.  Your patient asks to be tested.  Is she the best 
person to initiate testing in this family? 
64 (76)  
Your unaffected patient undergoes BRCA1/2 testing and is found to 
have a variant of uncertain significance (VUS) in the BRCA1 gene. 
What does this mean? 
83 (99)  
The same patient asks how the VUS result will affect her care.  You 
tell her that her management will be based on her family history. 
True or false? 
73 (87)  
Your patient’s sister carries a VUS in the BRCA1 gene, should you 
test your healthy patient for this BRCA1 variant? 
25 (30)  
Your patient’s maternal family has a known BRCA1 pathogenic 
variant; there is no history of cancer in her father’s family.  What 
type of testing would you choose to offer your patient? 
55 (65)  
This same woman undergoes testing and does not carry the known 
familial pathogenic variant.  What is your interpretation of her risk of 
developing breast cancer? 
74 (88)  
Which gene pathogenic variant carries a higher lifetime risk of 
developing ovarian cancer? 
41 (49)  
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3.3 OPINION ANALYSIS 
All of the responses to the opinion questions were compared between the 
obstetricians/gynecologists and family practice physicians, using the Mann-Whitney test and no 
statistically significant differences of opinion were identified between the two groups. 
The first opinion-based question asked the respondents about their confidence in their 
ability to provide information regarding breast cancer genetics; the respondents were asked to 
select whether they felt not confident, somewhat confident, or completely confident.  Fifty 
participants (59.5%) indicated they were somewhat confident with BRCA cancer risks, while 
only 3 participants (3.6%) indicated they were completely confident.  With regard to BRCA 
inheritance, 37 (44%) respondents indicated they were somewhat confident and 6 (7.1%) 
participants were completely confident.  Thirty-seven participants (44.1%) were somewhat 
confident with medical management after BRCA testing, and no participants indicated they were 
completely confident.  Thirty-five (41.7%) respondents were somewhat confident with BRCA 
genetic test result interpretation and one participant indicated he/she was completely confident.  
Participants were least confident with the many BRCA testing methods, 30 participants (35.7%) 
were somewhat confident and 2 (2.4%) were completely confident.  Figure 3 is summarized bar 
graphs of the participant’s confidence levels. 
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Figure 3: Participants’ Confidence with Providing Breast Cancer Genetics Information 
 
Participants were asked which fellow health care professionals would be best qualified to 
provide genetic testing and counseling services.  The vast majority of participants, 97.6%, 
83.3%, and 97.6%, respectively, thought that medical geneticists, genetic counselors, and 
oncologists were the best professionals to address these concerns for the patient.  Respondents 
were split fairly evenly on their opinions regarding the qualifications of 
Obstetrician/Gynecologists and Nurse Specialists to provide BRCA testing and risk assessment to 
patients.  The respondents were also given the option to input additional professionals who they 
deemed were qualified to address patient’s risks, testing, and counseling; all additional responses 
were regarding trained family practice and primary care physicians.  Please see Figure 4 below 
for a graphical representation of all responses. 
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Figure 4: Participants’ Beliefs on Provider’s Qualifications 
 
When queried about whether they felt a population-based testing program would be cost 
effective, 85.7% of respondents did not believe it would be.  The majority of respondents, 
79.8%, indicated that they did not have adequate time or resources to provide BRCA testing to 
every female patient, over the age of 30.  However, when asked if they would be interested in 
future medical genetics and cancer risk assessment education, 75 (89.3%) participants indicated 
some level of interest. 
Participants were also asked to specify what factors would motivate them to incorporate 
BRCA gene testing into their practice (Table 3).  Forty-three participants, 51.2%, indicated they 
would be more motivated if there was population-based evidence that their patient population 
was at risk of carrying a pathogenic variant.  Thirteen respondents, 15.5%, would be motivated 
by being personally affected or having a family member affected by breast cancer.  Thirty 
respondents, 35.7%, would be motivated to incorporate testing if they had a patient with a BRCA 
pathogenic variant.  Forty-four participants, 52.4%, would be motivated to offer testing if their 
patients requested testing.  Forty-five respondents, 53.6%, indicated cost-benefit data would 
motivate them.  Thirty-one participants, 36.9%, indicated incorporation of cancer risk assessment 
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in electronic records to help red-flag appropriate patients would be a motivating factor to 
incorporate testing into their practice.  Fifty-nine participants, 70.2%, indicated their greatest 
motivator would be evidence-based professional society guidelines indicating the utility of 
population-based testing.  Finally, 4 individuals, 4.8%, indicated they were not interested or 
motivated to incorporate BRCA testing into their practice.  
 
Table 3: Motivators to Incorporate BRCA Testing into Practice 
Proposed Motivator 
Participants 
n (%) 
Population evidence that your patient population is at increased 
risk for carrying a BRCA pathogenic variant. 43 (51) 
Being personally affected by breast cancer or having a close 
family member or friend with breast cancer. 13 (15) 
Having a patient with a BRCA pathogenic variant. 30 (36) 
Patients requesting testing. 44 (52) 
Cost/benefit data. 45 (54) 
Evidence-based professional society guidelines. 59 (70) 
If the electronic health record provided a cancer risk 
assessment to flag appropriate patients. 31 (37) 
Not interested or motivated to incorporate this testing into my 
practice. 4 (5) 
 
 
The final opinions collected from the participants were answered on a scale, strongly 
disagree, disagree, neutral, agree, and strongly agree; the participants were given a number of 
statements with which they had to state agreement or disagreement (Table 4).  Fifty respondents, 
59.5%, disagreed with the statement that the benefits of population BRCA screening outweigh 
the risks; 8.3% agreed.  Thirty-four respondents, 42.7%, disagreed with the statement that 
population screening will reduce breast cancer morbidity and mortality, 38.1% were neutral on 
the matter. Fifty-four participants, 64.3%, felt that pathogenic variant carriers would feel like 
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they can better protect themselves from the future cancers; 10.7% disagreed with this statement.  
Thirty respondents (35.7%) believe BRCA testing will lead to stigmatization or discrimination, 
while 39.3% disagree with that statement.  Fifty-three respondents (63.1%) agree that a negative 
test result will lead to false reassurance of cancer risks.  Twenty-seven respondents, 32.1%, agree 
that a negative test result will lead to neglect of routine breast health surveillance; but 32 
participants (38.1%) disagree.  Forty-two respondents (50.0%) agree that pathogenic variant 
carriers will experience significant, long-term psychological and emotional distress; thirty-two 
participants (38.1%) felt neutral about the subject.   
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Table 4: Provider Opinions on Population BRCA Screening 
Statement 
Strongly 
Disagree  
n (%) 
Disagree  
n (%) 
Neither 
Agree 
nor 
Disagree 
n (%) 
Agree    
n (%) 
Strongly 
Agree     
n (%) 
The benefits of population BRCA 
screening outweigh the risks. 
7 (8) 43 (51) 27 (32) 6 (7) 1 (1) 
Population screening will reduce 
breast cancer morbidity and 
mortality. 
4 (5) 31 (37) 32 (38) 17 (20) 0 (0) 
Pathogenic variant carriers will 
feel like they can better protect 
themselves from future cancers. 
0 (0) 9 (11) 21 (25) 48 (57) 6 (7) 
Testing will lead to stigmatization 
or discrimination. 
7 (8) 26 (30) 21 (25) 29 (35) 1 (1) 
A negative test result will lead to 
false reassurance of cancer risks. 
1 (1) 13 (15) 17 (20) 50 (60) 3 (4) 
A negative test result will lead to 
neglect of routine breast health 
surveillance. 
2 (2) 32 (38) 23 (27) 24 (29) 3 (4) 
Carriers will experience 
significant, long-term 
psychological and emotional 
distress. 
0 (0) 10 (12) 32 (38) 40 (48) 2 (2) 
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4.0  DISCUSSION 
4.1 ANALYSIS OF QUESTIONNAIRE DATA 
The participation rate in this questionnaire was similar to, if not better than, similar physician 
knowledge studies14–16,20.  The fact that 47% of the respondents had more than 15 years of 
experience may mean this population may not be entirely representative of all OB/Gyns and 
family practice professionals.  The majority of the participants, 87%, indicated they had not 
received additional formal genetics training, this may be because physicians, midlevel providers 
and nurses were all included in this sample and they may not all have the same opportunities for 
genetics educational advancement Additionally, more women than men responded to the 
questionnaire and therefore, it is unknown if this is representative of providers in the UPMC 
system, as gender distribution of the email lists were not available. It may be possible that more 
women responded because the topic under study was of more personal interest to the female 
population and motivated them to complete the questionnaire.  The responses from each 
specialty group were equally representative when response rates were compared; 
Obstetrics/Gynecology responded at a rate of 24.5% and the family medicine group responded at 
a rate of 24.7%.  Although there were more OB/Gyn responses, the percentages of the total 
populations are comparable. 
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As shown by Wideroff et.al (2005), the OB/Gyns in this study also demonstrated 
statistically more accurate BRCA knowledge than the family practice individuals (p-value= 
0.016).  The questions that almost all respondents answered correctly were related to knowledge 
that BRCA genes are not the only breast cancer predisposition genes and the definition of a VUS.  
Only 73.8% knew that the Ashkenazi Jewish population had a higher prevalence of BRCA 
pathogenic variants; it is unclear if prior knowledge studies asked this question specifically. 
Also, in general, participants were not overly confident in their capabilities to provide 
patients with information about the BRCA genes.  A question that participants struggled to 
answer was how the BRCA genes are inherited, less than 60% indicated autosomal dominant 
inheritance, but 81% knew a child could inherit a BRCA pathogenic variant from their father.  
Based on the inheritance pattern question, however, it is not surprising that only about 50% of 
participants indicated a level of confidence in explaining BRCA inheritance to patients.  The 
study by Wideroff et.al (2005) found deficiencies with physician knowledge of inheritance, 
while Pal et.al (2013) indicated their physician population responded best to questions of BRCA 
inheritance; the data found by this questionnaire falls somewhere in between these two studies 
which may be attributed to the different populations and specialties that were assessed. 
Three questions were asked with regard to the cancer risks attributed to the BRCA genes, 
one was almost unanimously answered correctly with 97.6% agreeing that the BRCA genes are 
also associated with an increased risk of ovarian cancer as well as breast cancer.  However, only 
52.8% indicated that the highest lifetime risk associated with the BRCA1 gene is 87% and only 
48.8% knew that the BRCA1 gene was associated with higher ovarian cancer risks.  But when it 
came to their opinions of their skills associated with cancer risks, over 60% of participants 
 41 
indicated a level of confidence reporting risks; this seems worrisome considering the proportion 
of incorrect answers to the risk questions.   
Conversely, nearly 87% of respondents would manage a patient correctly if she received 
a VUS by treating her based on her family history.  Additionally, 88% of respondents knew that 
if a patient did not carry their familial pathogenic variant they should be followed as any member 
of the general population.  Yet, only 44.1% of participants indicated they were somewhat 
confident with management of individuals who have had BRCA testing and 42.9% of 
respondents felt some level of confidence with BRCA gene testing interpretations.  Though the 
specific questions were not the exact questions asked in prior studies12,15, the accuracy of 
responses to the management questions in this study was higher than other studies, which, found 
management to be an area requiring further education. 
Similar to past knowledge studies15,16, participants demonstrated knowledge deficits with 
regard to management for a patient whose family member carries a VUS.  Less than 30% of 
participants knew not to test the patient when a VUS was found within the family.  However, for 
other testing procedures, more than 65% of respondents knew to order single site testing for a 
patient whose family has a pathogenic variant.  Additionally, 76% knew an unaffected individual 
was not the most appropriate person to initiate the genetic testing within a family.  These 
questions represented the subject matter that the respondents were least confident answering; less 
than 40% of respondents indicated confidence in answering questions related to testing methods. 
When queried about which providers would be best to consent and inform patients of 
their risks, testing options, and results, respondents selected medical geneticists and oncologists 
most frequently, followed by genetic counselors.  Interestingly, only 83% of the respondents 
thought genetic counselors were qualified to perform these duties even though cancer genetic 
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counselors routinely perform these tasks.  The majority of respondents, 85.7%, indicated they did 
not believe population-based genetic testing could be a cost-effective venture, and since a cost-
effectiveness study has not been performed while considering BRCA sequencing in a general 
population, their opinion cannot yet be contradicted.  Nearly 80% of respondents indicated they 
were unable to currently support a population screening program.  However, 89% of participants 
still showed interest in learning more about medical genetics and cancer risk assessment, this has 
been previously reported by other studies and was supported by the results found from this 
questionnaire10,11,15. 
Wideroff, et.al (2005), recommended that motivating factors of physicians to incorporate 
cancer risk assessment into their practice be investigated.  This study approached this issue from 
a different perspective and assessed what factors motivate respondents to consider incorporating 
a population based screening program into their practice.  The majority of respondents, 70%, 
selected evidence-based professional society guidelines indicating the utility of population-based 
testing, as the greatest motivator for population –based screening.  The next greatest motivator 
was cost-benefit data, which contradicts the research by Marzuillo, et.al (2013) which revealed 
that physicians believed genetic testing should be performed regardless of cost-effectiveness 
data.  Patients requesting testing and population-based evidence that their patient population was 
at risk of carrying a pathogenic variant were selected as the net two motivators for incorporating 
population-based screening, selected by 52% and 51%, respectively.  Also of interest was the 
finding that four of the 84 participants (4.8%) indicated they would not be motivated to offer 
population-based BRCA screening; this will be important to consider in the future. 
The majority of respondents disagreed with the statements that the benefits of population 
BRCA screening would outweigh the risks, that population screening would reduce morbidity 
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and mortality due to breast cancer, that a negative genetic test will lead to neglect of routine 
breast health, and that BRCA testing will lead to stigmatization or discrimination.  Participants 
generally agreed with the following statements: pathogenic variant carriers would be better able 
to protect themselves from future cancers, negative genetic testing will lead to a false 
reassurance of cancer risks, and that pathogenic variant carriers will experience significant, long-
term psychological and emotional distress.  Some of the opinions expressed in this section 
contradict themselves, for example, the providers surveyed think a negative BRCA test will cause 
a patient to think she has lower cancer risks than that of the general population, but they do not 
believe these individuals will neglect their routine breast screening.  Also, they reportedly 
believe pathogenic variant carriers will be able to better protect themselves from cancers, but 
they do not think that population-based screening will reduce morbidity and mortality rates from 
breast cancer.  Perhaps some of these statements were either not worded well or were not well 
understood, leading to the contradictions mentioned. 
4.2 LIMITATIONS OF STUDY AND FUTURE DIRECTIONS 
One limitation of this questionnaire relates to the ordering of the questions.  There are two 
perspectives that suggest demographic questions should be placed at the end of the survey.  One 
perspective contends that participants will be more likely to complete demographic questions at 
the end if they are personal and not complex.  The second perspective is that participants, who 
disclose demographic information before completing a survey, may answer a question based on 
how they think someone in that demographic should answer, rather than how that participant, as 
an individual, actually feels36.  Unfortunately, individuals who did not complete the survey did 
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not get to the demographic questions and therefore their knowledge and opinion data could not 
be incorporated into the analysis.   
Another limitation to consider would be the population that was invited to participate in 
this study.  First, these physicians and advanced practice providers were all associated with the 
UPMC system, an academic medical center.  Although this provider population was selected 
based on ease of accessibility, it is not possible to know if these providers are representative of 
all clinicians, only OB/Gyn and Family Practice clinicians, or only the OB/Gyn and Family 
Practice clinicians of Western Pennsylvania.   
A future direction that is worthy to pursue is to further explore why 84% of the surveyed 
medical professionals specified they would not wish to undergo BRCA testing.    One possibility 
is that the participants are an informed population and feel that testing is not necessary based on 
their assessment of their personal risk.  Additional studies could determine whether this opinion 
is localized to this population or more wide spread.  It is possible that providers may feel this 
way because they are knowledgeable of the extensive management associated with having a 
BRCA pathogenic variant, and/or because they are concerned about stigmatization and 
discrimination.  Clarification of the participants’ reasoning for indicating they would not want to 
know their own BRCA pathogenic variant status is warranted to ensure their aversion to being 
tested would not affect their views on offering population screening to their patient population. 
As a future study it would be interesting to compare the beliefs of this study population 
on their own confidence levels with breast cancer genetics before and after answering the 
knowledge questions.  Alternatively, the survey could have individuals report their confidence 
levels and opinions before the knowledge section, at random, while other individuals complete 
the knowledge portion first, as it was in this study.  This may allow for more insight into the 
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depth of the provider’s beliefs on population-based BRCA screening since their opinions may be 
affected by their knowledge and this may be seen by reordering the questionnaires. 
Furthermore, now that a number of studies have demonstrated the important areas of 
cancer genetic testing that physicians are either uncomfortable with or have consistently 
answered incorrectly, future research should focus on effective training strategies to utilize in 
advance of the implementation of BRCA population screening.  Research has already shown 
education geared toward general practitioners was feasible, satisfactory, and a clinically 
applicable way to improve cancer genetics consultations37.  There are already provider 
educational programs in place to enhance provider knowledge of HBOC, such as the one 
facilitated by the National Coalition for Health Professionals Education in Genetics (NCHPEG).  
Some additional programs covering all aspects of breast cancer genetics are available through the 
Medical College of Wisconsin, the Oncology Nursing Society, and the Jackson Laboratory; 
Wisconsin, NCHPEG, and Jackson are all free programs offering CME credit.  Perhaps future 
ventures should focus on adapting old programs and making providers aware of the educational 
opportunities available to them to further their knowledge about HBOC and to earn CME/CEU 
credits.  No matter which route is utilized to prepare providers for population-based BRCA 
screening, the outcomes of physician education efforts should be monitored for efficacy. 
Future directions also need to include the developments of educational programs for the 
general public.  It may be beneficial to take direction from studies performed during the 
implementation of Cystic Fibrosis Carrier Screening.  Clayton et.al (1995), found no difference 
between the knowledge obtained from educational materials based on their form, print vs. 
recording, despite designing a video to be able to reach individuals who were less comfortable 
with reading information38.  Additionally, Myers, et.al (1994) found discordances between what 
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providers believed the general public would want to know about CF screening, and what 
members of the general public wanted to know39.  When educational programs for population 
BRCA screening are developed for the general public, the opinions of the public on what 
information is most important to them should be determined and included in the educational 
materials.  General public knowledge should also be assessed over time. 
4.3 PUBLIC HEALTH SIGNIFICANCE 
This questionnaire aimed to assess the readiness of physicians to implement a population-based 
BRCA screening protocol and therefore, this research has public health relevance.  By 
understanding the baseline knowledge of providers, information is gained to facilitate provider 
education to improve their clinical performance40.   Additionally, determining physician 
motivation to incorporate population screening into their practice is of use to increase 
compliance with the employment of a new protocol in their practice.  Moreover, it is hoped that 
any research that aims to provide additional services for patients, especially population 
screening, that has the potential to decrease the number of breast and ovarian cancer diagnoses 
and related death is of public health significance.  This has been  shown in the population-based 
screening of the Ashkenazi Jewish population, where it was estimated to result in 276 fewer 
ovarian cancer cases and 508 fewer breast cancer diagnoses19. 
 In a broader sense, there are additional public health concerns associated with a 
population wide BRCA screening program, many of which have already been raised by 
individuals in the medical and genetics communities22,27,28.  One such concern is VUS reporting 
and the proposed plan to not report VUS findings, however VUS results are found more often in 
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non-Caucasians.  A study from Ambry Genetics  reports VUS rates for BRCA1/2 upwards of 9% 
in the Asian population, 6 to 7% in the African American population, and about 5% in the 
Hispanic population; this is compared to approximately a 3% chance of finding a VUS in a 
Caucasian individual41.  The overarching concern is that these variants will be reclassified to 
pathogenic variants and the individuals who were found to carry them will not be notified of 
their cancer predisposition.  An additional concern is disparities between individuals of different 
ethnicities and socioeconomic status with regard to the availability of health care; women 
included in these groups (African Americans and Hispanics) often do not have access genetic 
counselors, may not be aware of genetic testing or may not be referred for genetic testing, and 
may be unable or unwilling to pursue risk-reducing interventions when found to carry a 
pathogenic variant27.  One additional concern is cultural acceptance of genetic testing, studies 
have shown certain cultural, ethnic, and religious beliefs have varying opinions on the utility and 
acceptability of genetic testing27,42.  If a significant proportion of the population does not 
participate in a population-based screen, then any estimated or potential benefits to the overall 
population will no longer be applicable.  
4.4 CONCLUSIONS 
The knowledge of OB/Gyns and family medicine providers was assessed using a questionnaire 
which asked them to answer BRCA-based knowledge questions in addition to sharing their 
opinions on who the best provider would be to implement population-based BRCA screening and 
which factors would influence them to incorporate population-based BRCA screening into their 
own practice.  The present study supports previous practitioner knowledge surveys which 
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showed specialists had better overall knowledge of breast cancer genetics; providers within 
obstetrics and gynecology had overall better knowledge scores as compared to family medicine.  
This may be due to the fact that the specialty of OB/Gyn focuses on women’s care and 
information about BRCA tends to be skewed toward women.  All participants showed knowledge 
deficits with testing protocols for variants of uncertain significance in addition to the inheritance 
of the BRCA genes.  It is concerning that those surveyed were over-confident, meaning they 
scored poorly but indicated they were confident, with regard to their abilities to inform patients 
of the cancer risks associated with BRCA pathogenic variants.  Also, the respondents indicated a 
lack of confidence with their abilities to communicate patient management after BRCA testing.  
The respondents specified two professional groups who would best be able to inform and consent 
patients for population BRCA screening, they were medical geneticists and oncologists.  If the 
respondents of this questionnaire were to start offering BRCA testing to their patients, however, it 
would seem that they would be more motivated to do so if there were professional society 
guidelines indicating the utility of population-based BRCA screening.   
The results obtained from this questionnaire identify previously unrecognized pitfalls in 
provider knowledge about breast cancer genetics, specifically BRCA cancer risks.  This study 
was also able to confirm prior research on other areas of knowledge, specifically VUS testing 
and BRCA inheritance.  New information was also obtained from this questionnaire in the form 
of provider beliefs on who should provide population-based screening, in addition to elucidating 
motivating factors of physicians to implement BRCA population-based screening.  These 
findings may, over time, help to guide the involvement and education of clinicians in 
implementing population-based screening of the BRCA genes.  There is significant research left 
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to be completed before population-based BRCA screening becomes a wide-spread program due 
to concerns that have been raised from the medical and genetics communities.. 
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APPENDIX A: CONSENT SCRIPT 
You are being invited to complete a questionnaire as part of a Masters level research study being 
conducted by a genetic counseling graduate student at the University of Pittsburgh.    
The purpose of this study is to gauge the level of knowledge and current practices of 
physicians and mid-level providers in the UPMC network on the topic of breast cancer genetics 
BRCA1/2 testing.  The findings of this study will help to determine the readiness of health care 
providers to offer BRCA gene screening and to identify areas where more education may be 
needed in the event that population based BRCA1/2 gene screening is initiated. 
This questionnaire is intended to measure the extent of your “off the cuff” knowledge, so 
there is no need to look-up any of the answers to these questions.  This questionnaire is intended 
to take 10 to 15 minutes to complete.  This is an anonymous questionnaire and your responses 
will not be identifiable in any way.   
By submitting this questionnaire, you are consenting to participate in this research study.  
Your participation is voluntary and may be terminated at any time by exiting the questionnaire.  
Your participation will help to identify knowledge gaps and current practice of BRCA1/2 gene 
testing.  Thank you in advance for your participation.  Your time and input are appreciated.  To 
begin the questionnaire, please click the “Arrow” button below. 
 
Contact Information 
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There are no foreseeable risks to you in completing this questionnaire, but should you 
have any questions or concerns about this research study please feel free to contact: 
 
 
Erin Winchester, BS 
Candidate for M.S. Genetic Counseling 
School of Public Health 
Genetic Counseling Intern 
Magee-Women’s Hospital 
Email: winchesteree@magee.edu 
 
Darcy Thull, CGC 
UPMC Cancer Genetics Program 
T: 412-641-1466 
Email: dthull@magee.edu 
 
Aleksandar Rajkovic, MD, PhD 
Magee-Women’s Hospital 
T: 412-641-8635 
Email: rajkovic@upmc.edu 
 
Mylynda Massart, MD, PhD 
UPMC Department of Family Medicine 
T: (412) 383-1550 
Email:massartmb@upmc.edu
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APPENDIX B: STUDY QUESTIONNAIRE 
POPULATION BRCA SCREENING QUESTIONNAIRE 
Knowledge Questions (correct answers are bolded): 
Q1 What is the mode of inheritance for pathogenic variants in the BRCA genes? 
 Autosomal Dominant 
 Autosomal Recessive 
 X-Linked 
 Mitochondrial 
 Unsure 
 
Q2 True or false, BRCA1/2 pathogenic variants account for all hereditary breast cancers. 
 True 
 False 
 
Q3 The BRCA pathogenic variant carrier rate in individuals of Ashkenazi Jewish (Eastern 
European Jewish) ancestry is higher than the carrier rate of the general population. 
 True 
 False 
 Unsure 
 
Q4 Your patient has an aunt on her father’s side who is a carrier of a BRCA1 pathogenic variant.  
Is it possible that your patient could also carry this pathogenic variant? 
 Yes 
 No 
 Unsure 
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Q5 Your 35 year old female patient tests positive for a BRCA1 gene pathogenic variant.  What is 
her highest lifetime risk of developing breast cancer? 
 39% 
 87% 
 100% 
 Unsure 
 
Q6 Your healthy patient tests positive for a BRCA pathogenic variant.  She has an increased risk 
for breast and ovarian cancer. 
 True 
 False 
 
Q7 Your patient’s maternal family history is significant for breast cancer diagnosed prior to age 
50 in several women.  Several of the affected women are still living but have not been tested for 
pathogenic variants in BRCA1/2.  Your patient asks to be tested.    Is she the best person to 
initiate testing in this family? 
 Yes 
 No 
 Unsure 
 
Q8 Your unaffected patient undergoes BRCA1/2 testing and is found to have a variant of 
uncertain significance (VUS) in the BRCA1 gene. What does this mean? 
 A pathogenic variant was identified that causes hereditary breast and ovarian cancer 
syndrome. 
 A change was identified for which there is insufficient information to determine if it 
is harmful or benign to gene function. 
 A benign variation was identified. 
 The test needs to be repeated. 
 
Q9 The same patient asks how the VUS result will affect her care.  You tell her that her 
management will be based on her family history. 
 True 
 False 
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Q10 Your patient’s sister carries a VUS in the BRCA1 gene, should you test your healthy patient 
for this BRCA1 variant? 
 Yes 
 No 
 Unsure 
 
Q11 Your patient’s maternal family has a known BRCA1 pathogenic variant; there is no history 
of cancer in her father’s family.  What type of testing would you offer your patient? 
 Site-specific BRCA1 pathogenic variant analysis 
 Complete sequencing of BRCA1/2 
 Complete sequencing, plus deletion/duplication studies of BRCA1/2 
 Whole Exome Sequencing 
 
Q12 This same woman undergoes testing and does not carry the known familial pathogenic 
variant.  What is your interpretation of her risk of developing breast cancer? 
 She has an increased risk of developing breast and ovarian cancer. 
 She has an increased risk of developing breast cancer. 
 She has a risk similar to that of the general population of developing breast cancer. 
 She should be tested again to verify her cancer risks. 
 
Q13 Which gene pathogenic variant carries a higher lifetime risk of developing ovarian cancer? 
 BRCA1 
 BRCA2 
 
Opinion Questions: 
Q1 How confident are you in your ability to provide information to patients on the following 
components of breast cancer genetics? Please answer for each component. 
   Not Confident Somewhat Confident Completely Confident 
BRCA cancer risks        
BRCA inheritance        
Medical management        
BRCA testing methods       
BRCA test interpretation       
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Q2 Cancer risk assessment and genetic counseling provides patients with information about 
genetic testing and their risk of inherited cancer predisposition.  Which of the following health 
care providers would you consider to be qualified to provide these services to your patients? 
Please make a selection for each profession. 
            Yes  No      Not Sure 
OB/Gyn         
Medical Geneticist        
Oncologist         
Nurse Specialist        
Certified Genetic Counselor       
Other          
Q2.1 If you selected 'yes' for "Other," who else do you believe is qualified? 
  
Q3 Have you or would you wish to undergo BRCA testing? 
 Yes 
 No 
 Unsure 
 
Q4 In the general population the chance to have a BRCA1/2 pathogenic variant is less than 1%.  
Do you think population based BRCA testing would be a cost-effective venture, meaning the cost 
of testing every woman outweighs or is equal to the cost of treating and managing the women 
who are found to have BRCA pathogenic variants? 
 Yes 
 No 
 Unsure 
 
 
Q5 Do you feel you have adequate time and resources to test every woman over the age of 30 
that comes to your practice?  
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 Yes 
 No 
 Unsure 
 
Q6 How interested would you be in furthering your medical genetics and cancer risk assessment 
education? 
 Very Interested 
 Somewhat Interested 
 Not Interested 
 Unsure 
 
Q7 What is or would be the strongest motivator to incorporate BRCA gene testing into your 
practice? Please select all that apply to you. 
 Population evidence that your patient population is at increased risk for carrying a BRCA 
pathogenic variant. 
 Being personally affected by breast cancer or having a close family member or friend 
with breast cancer. 
 Having a patient with a BRCA pathogenic variant. 
 Patients requesting testing. 
 Cost/benefit data. 
 Evidence-based professional society guidelines. 
 If the electronic health record provided a cancer risk assessment to flag appropriate 
patients. 
 Not interested or motivated to incorporate this testing into my practice. 
  
Q8 To what extent do you agree or disagree (strongly disagree, disagree, neither agree nor 
disagree, agree, or strongly agree) with the following statements regarding population BRCA 
screening? Please make a selection for each statement. 
The benefits of population BRCA screening outweigh the risks.  
Population screening will reduce breast cancer morbidity and mortality.  
Pathogenic variant carriers will feel like they can better protect themselves from future cancers. 
Testing will lead to stigmatization or discrimination.  
A negative test result will lead to false reassurance of cancer risks.  
A negative test result will lead to neglect of routine breast health surveillance.  
Carriers will experience significant, long-term psychological and emotional distress.  
 
Demographic Questions: 
Q1 Gender: 
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 Male 
 Female 
 
Q2 How long have you been practicing medicine? 
 Still in residency 
 < 5 years 
 5-10 years 
 10-15 years 
 >15 years 
 
Q3 What type of practice setting do you currently work in? 
 Private 
 Locum tenens 
 Hospital Based 
 Academic 
 Other ____________________ 
 
Q4 What is your practice specialty? 
 OB/Gyn 
 Family Practice 
 Internal Medicine 
 Mid-level provider (Nurse Practitioner, Physician's Assistant, etc.) 
 Other ____________________ 
 
Q5 Does your office/practice currently provide BRCA testing to your patients? 
 Yes 
 No 
 I refer them to genetics 
 
 
 
Q6 Have you personally provided genetic counseling about BRCA1/2 to a patient? 
 Yes 
 No 
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Q7 Have you received any formal genetics training, outside of medical school/training? 
 Yes 
 No 
 
Q8 Do you have a personal or family history of breast or ovarian cancer? 
 Yes 
 No 
 Unsure 
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APPENDIX C: IRB APPROVAL 
 
 
 
University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
 
Memorandum 
    
To: Erin Winchester 
From: IRB Office 
Date: 6/15/2015 
IRB#: PRO15030332 
Subject: Physician Knowledge of Breast Cancer Genetics 
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The above-referenced project has been reviewed by the Institutional Review 
Board.  Based on the information provided, this project meets all the necessary criteria 
for an exemption, and is hereby designated as "exempt" under section 
45 CFR 46.101(b)(2) 
 
 
Please note the following information: 
• Investigators should consult with the IRB whenever questions arise about 
whether planned changes to an exempt study might alter the exempt status. Use 
the "Send Comments to IRB Staff" link displayed on study workspace to 
request a review to ensure it continues to meet the exempt category.  
• It is important to close your study when finished by using the "Study 
Completed" link displayed on the study workspace. 
• Exempt studies will be archived after 3 years unless you choose to extend the 
study. If your study is archived, you can continue conducting research activities 
as the IRB has made the determination that your project met one of the required 
exempt categories.  The only caveat is that no changes can be made to the 
application. If a change is needed, you will need to submit a NEW Exempt 
application. 
Please be advised that your research study may be audited periodically by the University of Pittsburgh 
Research Conduct and Compliance Office. 
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